All In Biotech

Drug Trial Radar · NCT07930572

A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria (CSU)

A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled (With an Open-Label Part B-1 Cohort), Single Dose and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NN2802, in Healthy Participants and in Participants With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With Antihistamines

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Novelty Nobility, Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

NN2802 is a new product that is being developed for treating participants with CSU who remain symptomatic despite treatment with antihistamines. NN2802 is not yet an approved product and it can only be used in an experimental study like this one. The purpose of this study is to learn more about a new experimental drug called NN2802. NN2802 is an investigational fully human monoclonal antibody that inhibits c-Kit. c-Kit is involved in the survival, development, and activity of mast cells, which are important cells involved in allergic and inflammatory reactions. By inhibiting c-Kit, NN2802 may reduce mast cell numbers and activity and may help improve symptoms of CSU, such as hives, itching, and angioedema. The study will assess the safety, tolerability, pharmacokinetics (PK, amount of drug in your blood), pharmacodynamics (PD, how the drug affects your body), immunogenicity (whether your body develops antibodies against the study drug), and preliminary efficacy (whether the drug may improve CSU symptoms) of NN2802. It also aims to identify suitable doses and dosing schedules of NN2802 for use in future clinical trials. This study will be conducted at multiple study sites, involving around 44 to 46 participants in total, including healthy participants and participants with CSU who remain symptomatic despite treatment with antihistamines. The number of participants depends on how well the study participants tolerate the treatment and the number of dose groups studied.

Conditions

  • Healhty
  • Chronic Spontaneous Urticaria (CSU)

Interventions

  • NN2802Drug

    Investigational product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence of Adverse EventsTime frame: 14 weeks
  2. Part B: Incidence of Adverse EventsTime frame: 22 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.